Please assess the completion status of the following clinical trial:

Trial Title: Comparison Between FFR Guided Revascularization Versus Conventional Strategy in Acute STEMI Patients With MVD.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients between 18-85 years presenting with STEMI who will be treated with primary PCI in \< 12 h after the onset of symptoms\* and have at least one stenosis of \>50% in a non-IRA on QCA or visual estimation of baseline angiography and judged feasible for treatment with PCI by the operator.~  * Patients with symptoms for more than 12 hr but ongoing angina complaints can be randomised~Exclusion Criteria:~1. Left main stem disease (stenosis \> 50%)~2. STEMI due to in-stent thrombosis~3. Chronic total occlusion of a non-IRA~4. Severe stenosis with TIMI flow ≤ II of the non-IRA artery.~5. Non-IRA stenosis not amenable for PCI treatment (operators decision)~6. Complicated IRA treatment, with one or more of the following;~   * Extravasation,~  * Permanent no re-flow after IRA treatment (TIMI flow 0-1),~  * Inability to implant a stent~7. Known severe cardiac valve dysfunction that will require surgery in the follow-up period.~8. Killip class III or IV already at presentation or at the completion of culprit lesion treatment.~9. Life expectancy of \< 2 years.~10. Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, Bivaluridin, or Everolimus and known true anaphylaxis to prior contrast media of bleeding diathesis or known coagulopathy.~11. Gastrointestinal or genitourinary bleeding within the prior 3 months,~12. Planned elective surgical procedure necessitating interruption of thienopyridines during the first 6 months post enrolment.~13. Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.~14. Pregnancy or planning to become pregnant any time after enrolment into this study.~15. Inability to obtain informed consent.~16. Expected lost to follow-up.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- FFR-guided revascularisation strategy (Type: ACTIVE_COMPARATOR): In the FFR-group all flow limiting (FFR≤0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient. Such procedures can be performed in a second procedure which should take place within the same hospitalisation. All lesions with a FFR measurement of \>0.80 will not be treated.
- randomised to guidelines group (Type: PLACEBO_COMPARATOR): In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place. The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).

Based on this trial design, predict the completion outcome and termination type (if applicable).